Really happy with how things are progressing. Revenue came in at the upper end of where I'd thought (I'd hoped for around 3-3.25m).
Its good to see new products under development with surgeons and anaesthetists, which ultimately diversifies and offers stability in future revenue streams. Ardo gains are still yet to be seen in full (again I'm of the belief that these could be rather sizeable to MLA in the medium term).
A solid growing cash balance and improvements in working capital alongside contracts signed with large respectable customers (in the Victorian Govt) lends credit to the ability to a trusted company that can deliver to scale.
Overall, I'm considering a top up, to an already overweight position. Certainly in my view it fully justifies a SP nearing 52week highs (5.9c ^ +7% today), and current levels attribute little value to the potential of further balance sheet gains IMO.
as always IMO, DYOR etc.
MLA Price at posting:
5.9¢ Sentiment: Buy Disclosure: Held
